KRAS and neoplasm: ACBI3 degraded and inactivated 13 of the 17 most common KRAS mutants (including G12D and G12V) and wild‐type KRAS while sparing HRAS and NRAS.[11b] More recently, pan‐KRAS degraders engaging the lysosomal degradation pathway has also gained achievement, represented by the tumor‐targeting KRAS degrader (TKD).